There is also interest in CLDN4 and CLDN9 as markers of drug resistance; for instance, CLDN9 upregulation in breast cancer was associated with chemotherapy failure (94), suggesting that targeting CLDN9 or its pathway could resensitize tumors to treatment. This evidence concerns the gene CLDN4 and breast cancer.